Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 422 of 5804
-
New hope for older leukemia patients: gentler chemo shows promise
Disease control Recruiting nowAcute lymphoblastic leukemia (ALL) is characterized by the abnormal proliferation of immature precursor cells, disrupting normal hematopoiesis and causing severe anemia and thrombocytopenia due to genetic mutations. Conventional treatment with intensive chemotherapy is limited fo…
Sponsor: Hospital General de Mexico • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Electric shocks + chemo: new hope for inoperable tumors?
Disease control Recruiting nowThis is an monocenter, single arm, clinical investigation that evaluate the impact of the method on the objective response rate (ORR) of visceral lesions undergoing electrochemotherapy. Electrochemotherapy is a well-defined method for the treatment of cutaneous and subcutaneous m…
Phase: NA • Sponsor: Istituto Oncologico Veneto IRCCS • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New glasses could slow Kids' worsening eyesight
Disease control Recruiting nowThe prevalence of myopia in Singapore is among the highest in the world, with 65 percent of our children being myopic by Primary 6, and 83 percent of young adults being myopic. As such, Singapore is often labelled as the "Myopia Capital of the World". By 2050, it is projected tha…
Phase: NA • Sponsor: Rodenstock GmbH • Aim: Disease control
Last updated Jun 26, 2026 18:34 UTC
-
New lung cancer pill targets resistant mutations in early trial
Disease control Recruiting nowHS-10504 is a fourth-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor targeting EGFR C797S mutation. This study will evaluate the safety, tolerability, pharmacokinetics and efficacy of HS-10504 in Chinese locally advanced or metastatic NSCLC.
Phase: PHASE1 • Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 18:26 UTC
-
Spinal gene injection aims to slow duchenne in toddlers
Disease control Recruiting nowThe primary objective of this study is to evaluate the safety and tolerability of a single dose of INS1201 via IT administration in ambulatory male participants with DMD.
Phase: PHASE1 • Sponsor: Insmed Gene Therapy LLC • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Sniffing out cancer: dogs and AI team up to detect breast cancer from breath
Diagnosis Recruiting nowThe goal of this study is to find out whether a system that uses trained detection dogs and artificial intelligence (AI) can identify breast cancer from a person's breath. Women who are scheduled to have routine breast cancer screening, such as a mammogram, ultrasound, or a biops…
Sponsor: SpotitEarly • Aim: Diagnosis
Last updated Jun 27, 2026 12:34 UTC
-
New pill combo aims to shield hearts in diabetes patients
Disease control Recruiting nowThis study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these conditions and do not have a history of heart failure. The purpose of this study is to find out if a medicine called vicadrostat, when …
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New combo therapy targets colorectal cancer in Mid-Stage trial
Disease control Recruiting nowThe study is being conducted to evaluate the safety, tolerability and efficacy of SHR-8068 injection in combination with anti-tumor therapies in subjects with colorectal cancer.
Phase: PHASE2 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New antibody shot shows promise in preventing malaria in african women
Prevention CompletedSafety and Efficacy of L9LS, a Human Monoclonal Antibody Against Plasmodium falciparum, in a Randomized, Double-Blind, Placebo-Controlled Trial of Women of Childbearing Potential (WOCBP) in Mali
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Prevention
Last updated Jun 27, 2026 13:05 UTC
-
New antibody injection could ease bulging eyes in thyroid disease
Disease control Recruiting nowThe primary objective of this study is to investigate the efficacy, safety, and tolerability of MHB018A, a humanized anti-IGF1R antibody, administered q4W for 6 months, in comparison to placebo, in the treatment of participants suffering from active TED.
Phase: PHASE3 • Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Cold plasma could save limbs in diabetic patients
Disease control Recruiting nowCritical limb ischemia is the end-stage manifestation of peripheral arterial disease (PAD), frequently presenting as ischemic rest pain, ulceration, or gangrene. Diabetes mellitus is a major risk factor for lower extremity arterial occlusion, with infrapopliteal arteries most com…
Phase: NA • Sponsor: Shenyang Medical College • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug combo aims to tackle Alzheimer's brain fog
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New COVID vaccine trial aims to outsmart evolving variants
⭐️ VACCINE ⭐️ CompletedThe purpose of this study is to evaluate the immunogenicity and safety of the recommended variant-containing formulations of mRNA-1283 COVID-19 vaccine (mNEXSPIKE®) within the current epidemiological environment.
Phase: PHASE4 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 09, 2026 00:00 UTC
-
New hope for neuroendocrine tumors: zanzalintinib takes on everolimus
Disease control Recruiting nowThe primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.
Phase: PHASE2, PHASE3 • Sponsor: Exelixis • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Zapping seizures away: laser treatment offers new hope for epilepsy patients
Disease control Recruiting nowHow does magnetic resonance-guided laser interstitial thermal therapy (MRgLITT) impact clinical prognosis in mesial temporal lobe epilepsy (mTLE)?
Phase: NA • Sponsor: Beijing Tiantan Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Experimental cocktail aims to shrink untreatable esophageal tumors
Disease control Recruiting nowThe combination of surufatinib with neoadjuvant chemo-immunotherapy and definitive concurrent chemoradiotherapy represents a promising new therapeutic strategy that may further improve the prognosis of patients with unresectable locally advanced esophageal squamous cell carcinoma…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New hope for kidney cancer patients whose tumors return after immunotherapy
Disease control Recruiting nowSubstudy 03C is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03). The goal of substudy 03C is to evaluate the safety and efficacy of experimental combinations of investigational a…
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New heart procedure aims to ease chest pain and shortness of breath
Disease control Recruiting nowThis is a prospective, multicenter, randomized, parallel-controlled, superiority clinical trial designed to evaluate the efficacy and safety of a transcatheter intramyocardial septal radiofrequency ablation system for the treatment of patients with obstructive hypertrophic cardio…
Phase: NA • Sponsor: SuZhou Sinus Medical Technologies Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Can a modified interferon rein in early myelofibrosis?
Disease control OngoingThis is a phase 3 double-blind clinical trial arm to test Ropeginterferon alfa-2b (P1101) in adult patients with Primary Myelofibrosis (PMF) at early stage or low to medium risk. Participants will receive the study drug/placebo bi-weekly and have an assessment visit every 4 week…
Phase: PHASE3 • Sponsor: PharmaEssentia • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New drug cocktail aims to outsmart Hard-to-Treat colorectal cancer
Disease control Recruiting nowThis randomized, multi-site, three-part study will test a new treatment called BNT314, which is designed to help the body's own defense to fight cancer in combination with another new treatment (pumitamig, which is a cancer immunotherapy drug also known as BNT327 and PM8002) and …
Phase: PHASE1, PHASE2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC